SCHEMBL6455331

SCHEMBL6455331

CN(C)Cc1sc(C(C)(C)c2c(Cl)cc(-n3nc(C(=O)O)c(=O)[nH]c3=O)cc2Cl)nc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRA P10827 2/20 0.39
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
STAT1 P42224 1/20 0.33
THRB P10828 2/20 0.32
ATM Q13315 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MEN1 O00255 1/20 0.31
PTGER1 P34995 1/20 0.31
PIM1 P11309 1/20 0.30
PIM3 Q86V86 1/20 0.30
PIM2 Q9P1W9 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30
ACMSD Q8TDX5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6454151 0.92 THRA (0.32) THRAKMT2AL3MBTL1THRBATM
SCHEMBL6455618 0.80 THRA (0.42) THRACYP2D6MAPTKMT2AL3MBTL1
SCHEMBL5762275 0.76 KDM4E (0.43) MAPTKMT2ATHRBPTGDR2KDM4E
SCHEMBL6462050 0.75 P2RX7 (0.41) THRAMAPTKMT2ATHRBPTGDR2
SCHEMBL6453803 0.74 P2RX7 (0.39) THRAKMT2ATHRBMEN1
SCHEMBL6455333 0.73 P2RX7 (0.42) THRAKMT2ATHRBMEN1
SCHEMBL7142482 0.73 P2RX7 (0.38) THRAKMT2ATHRBMEN1
SCHEMBL6459750 0.72 P2RX7 (0.41) THRAKMT2ATHRBMEN1
SCHEMBL7139293 0.71 THRA (0.42) THRACYP2D6MAPTKMT2AL3MBTL1
SCHEMBL6462754 0.70 P2RX7 (0.41) THRAKMT2ATHRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894046-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-17 US disclosed
EP-1114046-B1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-04-23 EP disclosed
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed
EP-0987265-A1 Interleukin-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST THRA 1581/4885CYP2D6 201/4885MAPT 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.